April, 2012 -- The Clinical Trial Company (TCTC) Limited (Knutsford, UK); is pleased to announce that Her Majesty The Queen has graciously accepted to approve the Prime Minister’s recommendation that TCTC should receive the Queen’s Award for Enterprise in International Trade.
The Cheshire based company is celebrating its 10th Anniversary this year having been established in 2002. The award has been conferred in recognition of TCTC’s substantial growth in overseas revenue and commercial success over the last 3 years. Exports accounted for 80% of turnover and there has been impressive overseas earnings growth of 193%.
The company provides clinical contract research services to the Pharmaceutical, Biotech and Medical Device Industries and is expert in advanced products areas such as cell and gene therapies as well as orphan drug indications. The company has some of the largest Pharmaceutical Companies in the world as clients but is also able to provide a tailored drug development service to smaller companies bringing new drug and device products to market.
There has been significant expansion of sales in the Netherlands and USA with new sales to Finland and Italy. The company has established offices in Canada, Germany and Australia resulting in experienced staff able to provide highly specialized technical support in other native languages. The remarkable growth of the CLINICAL TRIAL Company is, in part, because it is a quality driven company having achieved ISO 9001-2008 certification.
The TCTC motto of 'Treat every client as if they are our only client' and the dedication and professionalism of our teams has allowed TCTC to develop a loyal and ever growing customer base since 2002. Speaking about the Queen’s Award Kerri Leeming, Clinical Operations Director and founder of TCTC, said: "I am extremely proud and honoured that we have been selected for such a prestigious award particularly during the Queen’s Diamond Jubilee year and our own 10th Anniversary. This award is recognition of a decade of hard work and I would like to thank our employees, customers and partners for their support, without which we would not have grown as we have over the last decade."
For further enquiries:
Ewan Campbell, Director Tel: +44 1565 733772
Kerri Leeming, Director Tel: +44 1565 733772
Notes for Editors
About The Clinical Trial Company:
The Clinical Trial Company was incorporated in 2002. The TCTC founders realised an opportunity existed within the CRO sector for a company targeting medium size clinical trials and innovative products which lacked a classical road map to the market. Large CROs prioritise studies from the big pharmaceutical companies, for good business reasons. However, this approach sometimes disadvantages their smaller clients who are equally keen to complete their clinical trials quickly.
TCTC specializes in advanced therapy drugs such as cell & gene therapy as well as first in class biotechnology products. These types of investigational drugs often do not follow the classical road map to approval. They are also often Orphan Drugs which are targeted at meeting the unmet clinical needs of rare diseases.
TCTC has an experienced management team that offers extensive experience working with the EMA, FDA and MHRA to all their clients. Customer satisfaction is the key to our success as we always aim to provide our clients with efficient resource management and an alternative to conventional off-the-shelf approval strategies which ignore the unique nature of each product and market
The TCTC has its headquarters in Pickmere, Knutsford, Cheshire (UK) with additional offices in Cambridge (UK), Berlin (Germany), Toronto and Montreal (Canada), as well as Sydney (Australia). TCTC has operating divisions covering all aspects of drug development which include The CRA Company, The Regulatory Affairs Company, The Clinical Training Company and The CQA Company.
Additional information about TCTC can be found at www.theclinicaltrialcompany.com